Efficacy of Dendritic Cell-Based Cancer Immunotherapy
- *Corresponding Author:
- Shigetaka Shimodaira
Center for Advanced Cell Therapy
Shinshu University Hospital
Fax: +81-263- 37-3580
E-mail: [email protected]
Received Date: January 16, 2016; Accepted Date: January 25, 2016; Published Date: January 28, 2016
Citation: Shimodaira S, Higuchi Y, Yanagisawa R, Okamoto M, Koido S (2016) Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Biochem Anal Biochem 5:240. doi:10.4172/2161-1009.1000240
Copyright: © 2016 Shimodaira S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Dendritic cells (DCs) have antigen-specific bioactivity against tumor-associated antigens. The acquisition of tumor immunity with DC vaccination could be determined using both tetramer analysis and interferon γ-producing clones in enzyme-linked immunosorbent spot assays. A combination of DC vaccination with low-dose metronomic therapy and chemoradiotherapy would contribute to an enhanced acquired immunity for cancer therapy. The efficacy of DC vaccination may provide a survival benefit in some patients with cancer by achieving a prolonged quality-adjusted life year.